Evaluating plasma antinuclear autoantibody profile as a prognostic biomarker in lymphoma.

IF 3.4 2区医学 Q2 ONCOLOGY

BMC Cancer Pub Date : 2024-11-26 DOI:10.1186/s12885-024-13198-2

Cuiling Zheng, Ruyun Gao, Yanrong Wang, Xiaohong Han

{"title":"Evaluating plasma antinuclear autoantibody profile as a prognostic biomarker in lymphoma.","authors":"Cuiling Zheng, Ruyun Gao, Yanrong Wang, Xiaohong Han","doi":"10.1186/s12885-024-13198-2","DOIUrl":null,"url":null,"abstract":"Background: Research on the antinuclear antibodies (ANA) profile across different pathological subtypes of lymphoma was limited. Our study aimed to assess ANA profile and investigate its potential prognostic value in lymphoma.Method: We collected plasma samples from 139 lymphoma patients and analyzed the expression of plasma ANA, SSA, and SSB using the enzyme-linked immunosorbent assay (ELISA). Additionally, we focused on B-cell non-Hodgldn's lymphoma (B-NHL) for survival analysis.Results: Influencing factors for ANA profile levels included age (ANA: P = 0.0035, SSA: P = 0.0553, SSB: P = 0.0025), gender (SSA: P = 0.0436), serum IgG (ANA, P = 0.0385; SSA, P = 0.0175; SSB, P = 0.0291), and erythrocyte sedimentation rate (ESR) (SSA: P = 0.0380). In subtype comparisons, ANA and SSB levels were significantly lower in low-grade B-NHL compared to Hodgkin lymphoma (HL) (low-grade B-NHL vs. NHL: ANA, P = 0.0107; SSB, P = 0.0126). Aggressive NHL exhibited a higher ANA profile compared to indolent NHL (aggressive NHL vs. indolent NHL: ANA, P = 0.0262; SSA, P = 0.0136; SSB, P = 0.0280). Kaplan-Meier analyses identified SSA and SSB as potential prognostic biomarkers in patients with B-NHL undergoing chemotherapy.Conclusion: Our study evaluated ANA profile in various subtypes of lymphoma and demonstrated the prognostic value of autoantibodies in predicting clinical outcomes. The results highlight the potential of incorporating ANA profile into the prognostic assessment of lymphoma.","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"24 1","pages":"1451"},"PeriodicalIF":3.4000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-024-13198-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Research on the antinuclear antibodies (ANA) profile across different pathological subtypes of lymphoma was limited. Our study aimed to assess ANA profile and investigate its potential prognostic value in lymphoma.

Method: We collected plasma samples from 139 lymphoma patients and analyzed the expression of plasma ANA, SSA, and SSB using the enzyme-linked immunosorbent assay (ELISA). Additionally, we focused on B-cell non-Hodgldn's lymphoma (B-NHL) for survival analysis.

Results: Influencing factors for ANA profile levels included age (ANA: P = 0.0035, SSA: P = 0.0553, SSB: P = 0.0025), gender (SSA: P = 0.0436), serum IgG (ANA, P = 0.0385; SSA, P = 0.0175; SSB, P = 0.0291), and erythrocyte sedimentation rate (ESR) (SSA: P = 0.0380). In subtype comparisons, ANA and SSB levels were significantly lower in low-grade B-NHL compared to Hodgkin lymphoma (HL) (low-grade B-NHL vs. NHL: ANA, P = 0.0107; SSB, P = 0.0126). Aggressive NHL exhibited a higher ANA profile compared to indolent NHL (aggressive NHL vs. indolent NHL: ANA, P = 0.0262; SSA, P = 0.0136; SSB, P = 0.0280). Kaplan-Meier analyses identified SSA and SSB as potential prognostic biomarkers in patients with B-NHL undergoing chemotherapy.

Conclusion: Our study evaluated ANA profile in various subtypes of lymphoma and demonstrated the prognostic value of autoantibodies in predicting clinical outcomes. The results highlight the potential of incorporating ANA profile into the prognostic assessment of lymphoma.

查看原文本刊更多论文

评估作为淋巴瘤预后生物标志物的血浆抗核自身抗体谱。

背景：对不同病理亚型淋巴瘤的抗核抗体（ANA）谱的研究有限。我们的研究旨在评估抗核抗体谱，并探讨其在淋巴瘤中的潜在预后价值：我们收集了 139 例淋巴瘤患者的血浆样本，并使用酶联免疫吸附试验（ELISA）分析了血浆 ANA、SSA 和 SSB 的表达。此外，我们还重点对B细胞非霍奇金淋巴瘤（B-NHL）进行了生存分析：ANA概况水平的影响因素包括年龄（ANA：P = 0.0035；SSA：P = 0.0553；SSB：P = 0.0025）、性别（SSA：P = 0.0436）、血清IgG（ANA：P = 0.0385；SSA：P = 0.0175；SSB：P = 0.0291）和红细胞沉降率（ESR）（SSA：P = 0.0380）。在亚型比较中，低分化 B-NHL 的 ANA 和 SSB 水平明显低于霍奇金淋巴瘤（HL）（低分化 B-NHL vs. NHL：ANA，P = 0.0107；SSB，P = 0.0126）。侵袭性 NHL 的 ANA 高于非侵袭性 NHL（侵袭性 NHL 与非侵袭性 NHL：ANA，P = 0.0107；SSB，P = 0.0126）：ANA，P = 0.0262；SSA，P = 0.0136；SSB，P = 0.0280）。Kaplan-Meier分析发现，SSA和SSB是接受化疗的B-NHL患者的潜在预后生物标志物：我们的研究评估了不同亚型淋巴瘤的ANA概况，证明了自身抗体在预测临床结果方面的预后价值。结果凸显了将ANA谱纳入淋巴瘤预后评估的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Cancer 医学-肿瘤学

CiteScore

6.00

自引率

2.60%

发文量

1204

审稿时长

6.8 months

期刊介绍： BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.